Category - News

Markets

Leerink starts Puma Biotech at MP; PT $21

Leerink launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “market perform” rating and $21 price target. The stock closed at $25.33 on Jan. 16. Puma is a single-product commercial-stage biotech company...

January 17, 2019

Developments

Adamas Finance subscribes for $5-million of PharmaJet bonds

Adamas Finance Asia intends to subscribe for up to $5-million in a convertible bond offering by closely-held PharmaJet, the maker of needle-free injection devices. The PharmaJet injectors have received FDA approval, CE...

January 17, 2019

Executive Moves

Ocutrx Vision names Dr. Linda Lam as chief scientific and strategy officer

Closely-held Ocutrx Vision Technologies appointed Dr. Linda Lam as chief scientific and strategy officer to guide new technology development, and help align current and future R&D efforts, industry trends and growth...

January 16, 2019

Markets

Echelon starts Kalytera Therapeutics at speculative buy; PT 30 cents

Echelon Wealth Partners initiated coverage of Kalytera Therapeutics (TSXV:KALY) with a “speculative buy” rating and price target of 30 cents. The stock closed at 8.5 cents on Jan. 14. Kalytera is developing the...

January 15, 2019

Developments

Canopy Growth receives NY hemp license; plans to establish U.S. commercial operations

Canopy Growth (TSX:WEED) (NYSE:CGC) received a licence from New York State to process and produce hemp and will establish large-scale hemp extraction and product manufacturing in the state. Subject to board approval of...

January 14, 2019

Developments

IntelGenx, Tilray working to launch cannabis-infused VersaFilm in late-2019

IntelGenx (TSXV:IGX; OTCQX:IGXT) updated its cannabis-infused VersaFilm product co-development program with Tilray (NASDAQ:TLRY), following recently proposed Government of Canada amendments to the Cannabis Act that...

January 14, 2019

Markets

Noble starts Dyadic at OP; PT $4

Noble Capital Markets initiated coverage of Dyadic International (OTC:DYAI) with an “outperform” rating and price target of $4. The stock closed at $1.96 on Jan. 9. Over the past two decades, Dyadic has developed an...

January 10, 2019

Developments

Echelon reiterates Profound Medical as Top Pick

Echelon Wealth Partners reiterated Profound Medical’s Top Pick status (TSX:PRN; OTCQX:PRFMF) and maintained its “buy” rating and $3 price target. The stock closed at 74 cents on Jan. 9. Analyst Doug Loe writes that...

January 10, 2019

Markets

Piper Jaffray starts Canopy Growth at OW; PT $40

Piper Jaffray launched coverage of Canopy Growth (NYSE:CGC; TSX:WEED) with an “overweight” rating and $40 price target. The stock was quoted at $32.16, up $2.52, around midday on Jan 9. “While it is difficult to...

January 9, 2019

Developments

Fibrocor, Galapagos NV in development pact for fibrotic diseases

Closely-held Fibrocor Therapeutics, and Galapagos NV (Euronext, NASDAQ:GLPG), of Belgium formed a partnership for the development of therapeutics to treat fibrotic diseases of the kidney and other organs. In 2017, MaRs...

January 8, 2019

Category - News

Subscribe